Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Industry Says MDR Implementation 'Too Slow' But Negative Economic Effects Still Largely Unreported

Executive Summary

The European Commission needs to be faster and more efficient in its implementation of the new EU Medical Device Regulation (MDR), say German manufacturers, watching the remaining months of transition time slip into single figures. A few economic operators have come clean about the pressure the MDR has brought to bear, but the suspicion is that many are choosing to keep quiet.   

You may also be interested in...



IMQ Appointment As Fourth Notified Body Under MDR: Good News But Big Questions

There are now four notified bodies designated under the new EU Medical Device Regulation. But that is not enough, and new designations do not mean immediate testing either.

Global Call To Rethink MDR Timing Sees Commission Dig Heels In Further

The calls for a delay in the implementation of the new EU MDR are becoming increasingly loud on the international front, with the US, for one, wanting to see a three-year postponement. Is the European Commission right to remain stubbornly attached to its deadline?

MedTech Forum 2019: Building Growth In The Outcomes Era

The European MedTech Forum’s CEO panel set out to address high-level global, long-range issues, but from the start it got log jammed in regulatory issues. Not in the script perhaps, but wholly understandable, as new EU regulations will have huge strategic importance for how companies do business – and in the case of start-ups, if they can continue to do business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel